文献速递胸部肿瘤头颈与中枢神经肿瘤

阿法替尼联合标准剂量西妥昔单抗治疗晚期实体瘤的1b期研究

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.
PubMed 文献 · Eur J Cancer · 2018-10-01

这项1b期开放标签试验评估阿法替尼联合西妥昔单抗在经重度治疗的晚期实体瘤患者中的安全性及抗肿瘤活性。Part A确定最大耐受剂量和推荐剂量为阿法替尼40 mg/日联合西妥昔单抗250 mg/m2/周;Part B在肺鳞癌、头颈鳞癌和其他实体瘤队列中评估该剂量,常见不良事件为腹泻和痤疮样皮炎,部分患者观察到疾病稳定。

要点

  • 推荐2期剂量为阿法替尼40 mg/日联合西妥昔单抗250 mg/m2/周。
  • 全部58例患者中最常见治疗相关不良事件为腹泻(63.8%)和痤疮样皮炎(43.1%)。
  • Part B中55.1%患者达疾病稳定,肺鳞癌75.0%、头颈鳞癌66.7%、其他肿瘤36.4%。

核心结论

  • 阿法替尼联合西妥昔单抗的推荐2期剂量为阿法替尼40 mg/日联合西妥昔单抗250 mg/m2/周。
  • 不良事件可预测且可管理,部分患者尤其肺鳞癌和头颈鳞癌患者观察到抗肿瘤活性。

研究设计与样本

  • 1b期开放标签试验,Part A采用3+3剂量递增设计评估最大耐受剂量,起始剂量为阿法替尼30 mg/日联合西妥昔单抗250 mg/m2/周(西妥昔单抗400 mg/m2负荷剂量后),递增至阿法替尼40 mg/日。
  • Part B在推荐剂量下进一步评估安全性和耐受性及初步抗肿瘤活性,纳入肺鳞癌、头颈鳞癌和其他实体瘤三个队列。
  • Part A治疗9例患者;Part B在推荐剂量下治疗49例患者(肺鳞癌12例、头颈鳞癌15例、其他肿瘤22例);全部58例患者纳入分析。

主要发现

  • 全部58例患者中最常见治疗相关不良事件为腹泻(63.8%)和痤疮样皮炎(43.1%)。
  • 总体最佳确认缓解为疾病稳定(53.4%);疾病控制平均持续时间4.5个月;中位无进展生存期2.6个月。
  • Part B中55.1%患者达疾病稳定(肺鳞癌75.0%、头颈鳞癌66.7%、其他肿瘤36.4%)。

关键数值与推荐

  • 最大耐受剂量和推荐剂量确定为阿法替尼40 mg/日联合西妥昔单抗250 mg/m2/周。

临床怎么用

  • 对于经重度治疗的晚期实体瘤患者,尤其肺鳞癌和头颈鳞癌,可考虑阿法替尼联合西妥昔单抗方案,但需关注腹泻和痤疮样皮炎等不良事件。

局限性

  • 研究对象为经重度治疗、未选择/EGFR野生型晚期实体瘤患者,Part B各队列样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 1b, open-label trial assessed the combination of afatinib, an ErbB family blocker, with cetuximab, an epidermal growth factor receptor (EGFR) monoclonal antibody, in heavily pretreated patients with unselected/EGFR wild-type, advanced solid tumours. In Part A, the maximum tolerated dose (MTD) of afatinib + cetuximab was evaluated using a 3 + 3 dose-escalation design; the starting dose was afatinib 30 mg/day plus cetuximab 250 mg/m2/week (after cetuximab 400 mg/m2 loading dose), escalating to afatinib 40 mg/day. Part B further evaluated safety and tolerability at the MTD and preliminary anti-tumour activity in three patient cohorts with squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and other solid tumours. Nine patients were treated in Part A; the MTD and recommended dose was determined as afatinib 40 mg/day plus cetuximab 250 mg/m2/week. In Part B, 49 patients were treated at the recommended dose (12 with squamous NSCLC, 15 with HNSCC and 22 with other tumours). The most common treatment-related adverse events (AEs) across all 58 patients were diarrhoea (63.8%) and acneiform dermatitis (43.1%). Overall, the best confirmed response was stable disease (SD; 53.4%); mean duration of disease control was 4.5 months; median progression-free survival was 2.6 months. In Part B, 55.1% of patients had SD (squamous NSCLC, 75.0%; HNSCC, 66.7%; other tumours; 36.4%). In conclusion, the recommended phase 2 dose was determined as afatinib 40 mg/day plus cetuximab 250 mg/m2/week. AEs were predictable and manageable, and anti-tumour activity was observed in some patients, particularly in those with squamous NSCLC and HNSCC. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT02020577.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gazzah A, Boni V, Soria JC, et al. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. Eur J Cancer. 2018. PMID: 30278378. doi:10.1016/j.ejca.2018.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。